Dimerized T-cell receptor fragment, its compositions and use
View Patent ↗Dimers of a peptide from the T-cell receptor (Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr) (SEQ ID NO:1) are disclosed for preventing the progression to AIDS in an animal model. Methods for delaying the progression to AIDS and restoring normal immunological responses in an animal model following infection are shown and comprise administering through various systemic routes dimeric T-cell receptor peptide Vβ CDR1 to restore normal levels of Th1 cytokines interleukin 2 and interferon-γ, which are suppressed following infection, and those of Th2 derived cytokines interleukin 5, interleukin 6, interleukin 10, and immunoglobulin G, which are stimulated following infection.
1. A dimer comprising a monomer that
(a) consists of, from the N-terminus to the C-terminus direction, the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1) with the proviso that, if the sequences are present as an aqueous solution, then at least 81% of the occurrences of the sequence are present as a dimer; or
(b) is a homolog of the β3 peptide of the T-cell receptor β chain clone YT35, the said β3 peptide consisting of, from the N-terminus to the C-terminus direction, the sequence Cys Lys Pro Ile Ser Gly His Asn Ser Leu Phe Trp Tyr Arg Gln Thr (SEQ ID NO:1), wherein the homolog has the sequence of a segment of another distinct human Vβ gene which segment corresponds to the same segment as the said β3 peptide and wherein the homolog has the sequence Cys-[X]-Trp-[Y], wherein [X] is a 10 or 11 amino acid sequence and wherein [Y] is a 4 amino acid sequence; or
(c) is a variant of the monomer of (a) or (b), wherein:
(i) the variant has the sequence Cys-[X]-Trp-[Y], wherein [X] is a 10 or 11 amino acid sequence that has the sequence of amino acids 2-11 of the β3 peptide of the T-cell receptor β chain clone YT35, which is Lys Pro Ile Ser Gly His Asn Ser Leu Phe, or the sequence of the same segment of another distinct human Vβ gene which segment corresponds to the same segment as the said β3 peptide; and
(ii) wherein [Y] is a 4 amino acid sequence that has the sequence of amino acids 13-16 of the β3 peptide of the T-cell receptor β chain clone YT35, which is Tyr Arg Gln Thr, or the sequence of the same segment of another distinct human Vβ gene which segment corresponds to the same segment as the said β3 peptide, except that, at one position in total within the [X] and [Y] sequences, there is a substitution wherein the dimer when administered as a dose of 200 μg/mouse to a C57BL/6 mouse infected with the LP-BM5 retrovirus, has the ability to normalize IL-4 secretion by mitogen-stimulated splenocytes of said mouse relative to a C57BL/6 mouse infected with the LP-BM5 retrovirus and treated with saline.
2. The dimer of claim 1 that is a homodimer.
3. A homodimer according to claim 2 , wherein each monomer of the homodimer consists of, from the N-terminus to the C-terminus direction, the sequence Cys Ser Pro Lys Ser Gly His Asp Thr Val Ser Trp Tyr Gln Gln Ala (SEQ ID NO:2).
4. A dimer according to claim 1 with the proviso that, if the sequences are present as an aqueous solution, then at least 81% of the occurrences of the sequences are present as a dimer.
5. A pharmaceutical formulation comprising a dimer according to claim 1 and a pharmaceutically acceptable excipient.
6. A method for treating an infectious disease caused by an immunodeficiency-type retrovirus, the method comprising administering a composition comprising a dimer of claim 1 to an animal in need of treatment.
7. The method of claim 6 wherein the immunodeficiency-type retrovirus is a C-type retrovirus or a lentivirus.
8. The method of claim 7 wherein the lentivirus is HIV-1, HIV-2, HIV-3, simian immunodeficiency virus (SIV), or feline immunodeficiency virus (FIV).
9. A pharmaceutical formulation comprising a dimer of claim 1 wherein at least 82%, 83%, 84%, 85%, 88%, 90%, 92%, 95%, 98%, 99%, 99.5%, 99.9%, 99.99%, 99.999% or substantially 100% of the occurrences of the sequences are present as a dimer.
10. A composition comprising a dimer of claim 1 and a further therapeutic agent.
11. The composition of claim 10 wherein the further therapeutic agent is a peptide or an immune-stimulating adjuvant.
12. The composition of claim 10 wherein the further therapeutic agent is useful in the treatment of HIV-infection.
13. The composition of claim 10 wherein the further therapeutic agent is an antibiotic or an anti-histamine.